Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. bio architect dlp 3d bio printer
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Downloads
Videos

Refine by
Date

  • Older

Bio Architect Dlp 3d Bio Printer Articles & Analysis: Older

26 news found

Matexcel Provides Expansive Array of Bio-ink Products for Different Applications

Matexcel Provides Expansive Array of Bio-ink Products for Different Applications

Matexcel, a leading innovator in advanced materials and bioengineering, today announced its diverse portfolio of bio-ink products, empowering researchers across various fields to unlock the potential of 3D bioprinting. This comprehensive range, featuring tailored bio-inks for specific applications, paves the way for revolutionary advancements in regenerative medicine, drug discovery, and beyond. ...

ByMatexcel


Stefan Blomsterberg appointed as new CEO of Cellink Bioprinting AB

Stefan Blomsterberg appointed as new CEO of Cellink Bioprinting AB

Stefan Blomsterberg has been appointed as the new CEO of CELLINK. Cecilia Edebo, current CEO, requested earlier this year to resign from her position to pursue a new career opportunity outside the BICO Group. At the time of her resignation, a recruitment process was initiated which concluded in the appointment of Stefan Blomsterberg. Stefan Blomsterberg (born 1964) brings 20+ years of experience ...

ByCELLINK


CELLINK and Ossiform Enter a Strategic Partnership to launch Ossi Ink, a printable bioink based on Ossiform’s P3D Bone material

CELLINK and Ossiform Enter a Strategic Partnership to launch Ossi Ink, a printable bioink based on Ossiform’s P3D Bone material

CELLINK and Ossiform have entered a strategic partnership to join forces to commercialize a ready-to-print bioink based on Ossiform’s existing biomaterial. Sales of the material will begin in 2024 and will be distributed co-exclusively through CELLINK’s commercial channels. Bone regeneration is one of the fastest growing research disciplines, given the massive impact it can have on ...

ByCELLINK


CELLINK Announces CELLINK Vivoink: Our First Medical-Grade Bioink

CELLINK Announces CELLINK Vivoink: Our First Medical-Grade Bioink

CELLINK, a global leader in bioprinting technologies, is proud to announce a pioneering innovation in the field of regenerative medicine and tissue engineering with the launch of CELLINK Vivoink, the first-ever medical-grade bioink specially designed to support researchers on their clinical translational journey. CELLINK Vivoink is optimized for superior printability, mechanical stability, and ...

ByCELLINK


CELLINK and the University of California, San Diego Partner to Open a 3D Bioprinting Centre of Excellence

CELLINK and the University of California, San Diego Partner to Open a 3D Bioprinting Centre of Excellence

CELLINK, a leading global provider of bioprinting technologies, and the University of California, San Diego (UCSD), a world-renowned research institution, are pleased to announce their partnership to establish a 3D bioprinting Centre of Excellence. This partnership aims to facilitate the utilization of advanced bioprinting technologies and promote cutting-edge research in the fields of drug ...

ByCELLINK


Carcinotech and CELLINK Enter a Partnership to Develop and Commercialize Protocols for Cancer Models to Provide Improved Speed and Accuracy in the Drug Development Processes

Carcinotech and CELLINK Enter a Partnership to Develop and Commercialize Protocols for Cancer Models to Provide Improved Speed and Accuracy in the Drug Development Processes

Carcinotech and CELLINK are pleased to announce a collaborative partnership to develop and commercialize protocols for the biofabrication of 3D bioprinted tumor models based on cancer cell lines that improve accuracy and rapidly speed up drug development processes, driving down development costs and enabling an improved output. The protocols will be available for use on the BIO CELLX system ...

ByCELLINK


3DBio Therapeutics and the Microtia-Congenital Ear Deformity Institute Conduct Human Ear Reconstruction Using 3D-Bioprinted Living Tissue Implant in a First-in-Human Clinical Trial

3DBio Therapeutics and the Microtia-Congenital Ear Deformity Institute Conduct Human Ear Reconstruction Using 3D-Bioprinted Living Tissue Implant in a First-in-Human Clinical Trial

3DBio Therapeutics (3DBio), a clinical-stage regenerative medicine company, and the Microtia-Congenital Ear Deformity Institute announced they have conducted a human ear reconstruction using the AuriNovo™ implant, an investigational, patient-matched, 3D-bioprinted living tissue ear implant. The groundbreaking reconstructive procedure in the first-in-human Phase 1/2a clinical trial is ...

By3DBio Therapeutics


MatTek Enters Distribution Agreement and Strategic Partnership with Cell4Pharma

MatTek Enters Distribution Agreement and Strategic Partnership with Cell4Pharma

MatTek Life Sciences will distribute Cell4Pharma’s ciPTEC renal cells and utilize the technology in the development of a new in vitro kidney model. MatTek Life Sciences, a Boston-area tissue engineering company and a member of the BICO Group, announced today it has entered into a distribution agreement and strategic partnership with Cell4Pharma, a Netherlands-based company specializing ...

ByBICO - The Bio Convergence Company


BICO acquires Allegro 3D, adding new light-based 3D bioprinting technology – complementing the existing offering of application tailored products

BICO acquires Allegro 3D, adding new light-based 3D bioprinting technology – complementing the existing offering of application tailored products

Adding Allegro 3D to the portfolio enables BICO Bioprinting to strengthen its position as the global leader in providing 3D bioprinters. BICO has a robust portfolio of bioprinters, utilizing extrusion based, 2PP and DLP technologies. BICO has acquired all the shares in San Diego-based Allegro 3D Inc. (“Allegro 3D”) for an up-front enterprise value of USD 6 million. Additionally, ...

ByBICO - The Bio Convergence Company


The BICO Group has been awarded 7 iF design awards for excellence in product design

The BICO Group has been awarded 7 iF design awards for excellence in product design

Handed to products that excel in their design and vision, the iF awards are voted on by a jury of 132 leading designers from across the globe with the goal to identify products which demonstrate the adoption of modern design trends and outstanding craftsmanship. For the third year in a row, BICO has taken home the award and extends its haul to 11 iF design awards in total, officially ranking ...

ByBICO - The Bio Convergence Company


MatTek Announces Production and Shipping of EpiOral Tissues from European Facility to Better Service the Wider Market

MatTek Announces Production and Shipping of EpiOral Tissues from European Facility to Better Service the Wider Market

MatTek Life Sciences will produce and distribute EpiOral from its production facility in Slovakia, continuing the BICO groups’ focus on providing on-demand tissues to the European market. MatTek Life Sciences, a Boston-area tissue engineering company and a part of the BICO Group, announced today its European facility in Bratislava, Slovakia, will begin producing and shipping EpiOral, a ...

ByBICO - The Bio Convergence Company


Poietis and Assistance Publique – Hôpitaux de Marseille (AP-HM) annouce the first installation of a 3D bioprinting platform for manufacturing implantable biological tissues in hospitals

Poietis and Assistance Publique – Hôpitaux de Marseille (AP-HM) annouce the first installation of a 3D bioprinting platform for manufacturing implantable biological tissues in hospitals

The installation of the NGB (Next-Generation Bioprinting) robotic bioprinting platform developed by Poietis in the Advanced Therapy Medicinal Product (ATMP) manufacturing area of the Hôpital de la Conception represents a world premiere and opens up very promising perspectives in regenerative medicine. The objective is now to start the first clinical trial of a 3D printed ...

ByPoietis


ASPECT BIOSYSTEMS TO PRESENT NEW DATA ON BIOPRINTED LIVER TISSUES AT AASLD LIVER MEETING 2021

ASPECT BIOSYSTEMS TO PRESENT NEW DATA ON BIOPRINTED LIVER TISSUES AT AASLD LIVER MEETING 2021

Presentation will highlight the development of functional 3D bioprinted co-cultured human hepatocyte spheroids for use as a liver tissue therapeutic Vancouver, BC, Canada, November 3, 2021 - Aspect Biosystems, a biotechnology company pioneering the development of bioprinted cell therapies as medicines of the future, will present new data on its bioprinted liver tissues at the The Liver Meeting ...

ByAspect Biosystems Ltd.


Aspect Biosystems And Jsr Corporation Enter Collaboration To Develop Bioprinted Vascularized Tissues For Regenerative Medicine

Aspect Biosystems And Jsr Corporation Enter Collaboration To Develop Bioprinted Vascularized Tissues For Regenerative Medicine

Aspect Biosystems, a privately held biotechnology company pioneering the development of bioprinted therapeutics, is pleased to announce a new joint development program with JSR Corporation, a global leader in advanced materials innovation. This collaboration builds on the existing partnership between the two companies and will see the combining of Aspect’s proprietary microfluidic 3D ...

ByAspect Biosystems Ltd.


UPM Biomedicals fights cancer with GrowDex®

UPM Biomedicals fights cancer with GrowDex®

Cancer is the second leading cause of death globally, and unfortunately a growing global burden. With an estimated 18 million cancer cases yearly around the world, cancer is one of the most significant public health challenges of the 21st century. UPM Biomedicals joins the fight against cancer with a wood-based hydrogel, GrowDex®. The hydrogel made of birch and water supports cell growth by ...

ByUPM


CELLINK and Atelerix team up to enable the shipping at room temperature of fragile 3D bioprinted constructs by the world’s bioprinting community

CELLINK and Atelerix team up to enable the shipping at room temperature of fragile 3D bioprinted constructs by the world’s bioprinting community

CELLINK and Atelerix announced today a partnership to bring to market Atelerix’s portfolio of innova­tive hydrogel biological encapsulation products, which preserve fragile biological samples for shipping at room temperature. Conven­tional shipping methods often involve storing cells and tissues in liquid nitrogen or dry ice, which requires a freeze-thaw process notorious for ...

ByAtelerix Ltd


Aspect Biosystems Appoints Ray Smith as Chief Financial Officer

Aspect Biosystems Appoints Ray Smith as Chief Financial Officer

Aspect Biosystems, a biotechnology company developing bioprinted therapeutics, is pleased to announce the appointment of Ray Smith as its new Chief Financial Officer. In his role as Chief Financial Officer, Ray will assume leadership responsibilities for financial management and business operations. “Since leaving the University of British Columbia’s campus and launching our ...

ByAspect Biosystems Ltd.


BIOLIFE4D Names Pharmaceutical Veteran Kate Lewis as President

BIOLIFE4D Names Pharmaceutical Veteran Kate Lewis as President

BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, today announced it has named Kate Lewis as President of the company. She joined BIOLIFE4D full time in early 2019 in a market and business development role before being elevated as the first female executive in Company history. Lewis brings more than 25 years of experience and ...

ByBIOLIFE4D


Poietis announces formation of Scientific Advisory Board and appoints two first prominent Regenerative Medicine experts

Poietis announces formation of Scientific Advisory Board and appoints two first prominent Regenerative Medicine experts

Poietis, 4D Bioprinting company, announces formation of Scientific Advisory Board (SAB) and appointment of two first prominent Scientists in Regenerative Medicine. The SAB will serve as a key strategic resource to Poietis as the company expands capabilities of Next- Generation Bioprinting (NGB) platform to therapeutic applications and develops first implantable tissues such as a ...

ByPoietis


3DBio Therapeutics Receives Orphan Drug Designation for AuriNovo™ for Ear Reconstruction in Microtia Patients

3DBio Therapeutics Receives Orphan Drug Designation for AuriNovo™ for Ear Reconstruction in Microtia Patients

3DBio Therapeutics, an emerging leader in the field of 3D-bioprinting for human therapeutic use, today announced it has received Orphan Drug Designation for AuriNovo™, an investigational combination product for reconstruction of the outer ear in patients with microtia. Microtia is a rare congenital disorder causing the outer ear (auricle) to be smaller than typical, misshapen, and sometimes ...

By3DBio Therapeutics

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT